A study of a combination of Trastuzumab and Capecitabine with or without Pertuzumab in patients with HER2-positive metastatic breast cancer Studie porovnávající kombinaci Trastuzumabu a Capec...

Update Il y a 4 ans
Reference: EUCTR2008-006801-17

A study of a combination of Trastuzumab and Capecitabine with or without Pertuzumab in patients with HER2-positive metastatic breast cancer Studie porovnávající kombinaci Trastuzumabu a Capecitabinu podávanou s nebo bez Pertuzumabu u pacientek s HER2 pozitivním metastatickým karcinomem prsu

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To compare progression-free survival (PFS) between the two treatment arms based on assessments by an independent review facility (IRF).


Inclusion criteria

  • HER2 positive metastatic breast cancer which has progressed after one line of trastuzumab-based therapy in the metastatic setting